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Abstract
Background: Minor physical anomalies (MPAs) have been found to be more prevalent in schizophrenia than control
participants in numerous studies and may index a potential endophenotype for schizophrenia.
Aim: To quantitatively define the magnitude of the difference in total MPA scores between patients with schizophrenia and
healthy controls; to determine the degree of manifestation in unaffected first-degree relatives compared to patients and
controls; and to investigate the degree of sensitivity among individual MPA items.
Methods: A systematic search was conducted on the literature pertaining to MPAs in patients with schizophrenia and
unaffected relatives. Effect sizes (Cohen’s d and odds ratios) and corresponding confidence intervals were combined using
the Comprehensive Meta-Analysis software package.
Results: A large difference was found when examining 14 studies comprising 1207 patients with schizophrenia and 1007
healthy controls (d=0.95, 95% CI=0.63, 1.27). Six studies involving relatives of individuals with schizophrenia showed a
medium effect size (d=0.45, 95% CI=0.29,0.62) between patients and relatives, but a small and non-significant effect size
(d=0.32, 95% CI=20.08, 0.73) between relatives and controls. The majority of MPAs items showed significant odds ratios
(1.26–9.86) in comparing patients and controls.
Conclusions: The findings indicate that medium effect size of MPAs have been demonstrated in patients with schizophrenia
as compared to healthy controls, and to a lesser extent in unaffected relatives. These findings are consistent with the idea
that MPAs may represent a putative endophenotype for schizophrenia. However, more research including first-degree
family members is warranted.
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Introduction
The endophenotype construct represents a promising approach to
facilitating investigations of schizophrenia, a disorder that is now
thought to be influenced by multiple genes as well as environ-
mental factors. Gottesman and Shields described an endopheno-
type as an internal, intermediate phenotype (i.e., not obvious to the
unaided eye) that fills the gap between genes and diseases [1].
Endophenotypes should be: (1) associated with the illness in the
population, (2) heritable, (3) state-independent, (4) found in
unaffected family members at a higher rate than in the general
population, and (5) shown to co-segregate with the illness within
families[2]. Multiple potential endophenotypes, such as specific
cognitive deficits and neurological soft signs, have been examined
in patients, relatives, and healthy controls [1,3].
Minor physical anomalies (MPAs) are suggested as an
endophenotype on account of the findings that MPAs present
more in patients than healthy controls and are state-independent
[4]. Weinberg and colleagues (2007) reviewed the studies on MPAs
in schizophrenia and pooled effect sizes calculated from 11 studies
by meta-analysis. The results revealed a high degree of difference
(d=1.13) between the patients with schizophrenia and healthy
controls [5]. In addition, several studies have investigated the
prevalence of MPAs in unaffected relatives of patients with
schizophrenia, though consistency across the research literature
has been limited. Therefore, we performed the present meta-
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24129analysis to: (1) update the literature about MPAs in patients with
schizophrenia and control comparisons, (2) quantify the magni-
tude of the mean difference between relatives and patients with
schizophrenia, and (3) determine the magnitude of the difference
between relatives of patients with schizophrenia and healthy
controls. As a secondary aim, we examined individual MPA items
to determine which specific MPAs manifest more commonly in
schizophrenia than in healthy controls across studies.
Methods
Literature Search
Relevant articles, published from 1968 through July 31
st 2011,
were identified using an extensive literature search of Elsevier
Science, Blackwell, Springer, PsycINFO, and Medline. The
keywords were: ‘‘minor physical anomalies,’’ ‘‘MPA,’’ ‘‘morpho-
logic signs,’’ ‘‘dysmorphic,’’ and ‘‘schizophrenia.’’ These search
procedures yielded 86 potential articles for review.
(a) Inclusion criteria. Studies selected for meta-analytic
review met the following criteria: (1) diagnoses were based on
diagnostic criteria for schizophrenia as operationalized in DSM-III,
DSM-III-R, DSM-IV, ICD-9, or ICD-10; (2) a standardized scale
was used to assess MPAs (e.g., the widely used Waldrop Scale [6]; (3)
a healthy control group or a sampleof first-degree relatives of patients
withschizophrenia wasincluded; and (4) MPA scores of at least twoof
the three groups (patients, relatives, and controls) were available as
means and standard deviations (SDs), or an effect size was calculable
via t or F test values. Based on the pool of available articles, using
these inclusion criteria resulted in 19 eligible studies (Figure 1).
Figure 1. The flow chart for the inclusion and exclusion of studies for the current meta-analysis.
doi:10.1371/journal.pone.0024129.g001
Figure 2. Effect sizes and confidence intervals for each study in
the meta-analysis involving patients with schizophrenia and
healthy controls.
doi:10.1371/journal.pone.0024129.g002
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included in the meta-analysis did not involve the same group of
subjects, for studies in which an overlap of sample or data was
identified, the one with the largest sample size was chosen. Several
studies from the same research groups had apparently overlapping
samples to varying degrees [7,8,9,10,11,12,13,14]. Four studies
were excluded after this procedure; thus, 14 studies remained that
included comparisons between patients and controls, and six
studies had data on first-degree relatives.
Statistical Analyses
Effect sizes (Cohen’s d) indexing the difference between groups
were calculated by taking the difference in means between two
groups, divided by the pooled standard deviation. Specifically, for
schizophrenia versus healthy controls, the difference in means
between two groups was the mean of the schizophrenia sample
minus the mean of the healthy controls. Similarly, for schizophre-
nia versus relatives and relatives versus healthy controls, the
difference in means were the mean of the schizophrenia group
minus the mean of relatives and the mean of the relatives minus
the mean of controls, respectively. The 95% confidence interval
(CI) was estimated to determine whether effect sizes were
statistically significant. Since the individual effect size distributions
may be heterogeneous across studies, the Q statistic was
computed. A significant Q statistic indicates heterogeneity of the
individual study effect sizes [15]. Based on the Q statistic,
moderator analyses were carried out to determine whether the
number of MPA scale items, sex ratio among patients, and sex
ratio among controls led to the heterogeneous results.
Meta-analysis has the potential to be affected by publication
bias. The most possible publication bias is the lack of published
studies yielding non-significant results [16]. The Orwin’s fail-safe
number estimates the number of non-significant, unpublished
studies that would overturne an overall statistically significant
observed effect to some specified and negligible level [17,18]. We
set the negligible level at 0.2, which indicates a weak and usually
non-significant effect size [19]. In addition, we set 0.1 as the mean
effect size of the hypothetical, additional ‘‘missing’’ studies.
Regarding the second aim, odds ratios (ORs) were calculated for
each specific MPA item from studies that reported the percentage
or the number represented in schizophrenia and healthy controls.
Then, combined ORs with 95% confidence intervals and
heterogeneity statistics were computed. The significant ORs (.1)
indicated that MPAs manifest more commonly in patients with
schizophrenia than in healthy controls.
All analyses were performed using the Comprehensive Meta-
Analysis Software package [20].
Results
Patients with Schizophrenia vs. Healthy Controls
Fourteen studies [8,13,14,21,22,23,24,25,26,27,28,29,30,31]
compared total MPA scores between patients with schizophrenia
and healthy controls, comprising 1207 patients and 1007 controls.
Table 1. Results of meta-analyses of MPAs in patients with schizophrenia, relatives of patients, and healthy controls.
N of studies N of subjects
std. diff in
means SE 95% CI Q-value Fail-safe N
SCZ vs. C 14 1207 SCZ,
1007 Controls
0.95 0.16 (0.63, 1.27) 150.56** 96
SCZ vs. R 6 339 SCZ,
303 Relatives
0.45 0.08 (0.29, 0.62) 5.04 16
R vs. C 6 303 Relatives,
266 Controls
0.32 0.21 (20.08, 0.73) 32.03** 8
SCZ: Schizophrenia patients.
C: Healthy Controls.
R: Relatives of schizophrenia patients.
**p,0.01.
doi:10.1371/journal.pone.0024129.t001
Figure 3. Effect sizes and confidence intervals for each study in
the meta-analysis involving patients with schizophrenia and
relatives.
doi:10.1371/journal.pone.0024129.g003
Figure 4. Effect sizes and confidence intervals for each study in
the meta-analysis involving unaffected relatives and healthy
controls.
doi:10.1371/journal.pone.0024129.g004
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analysis. The mean effect sizes for total MPA scores, along with
their 95% CIs and homogeneity statistics are shown in Table 1.
The difference between patients and controls was in the moderate
range (d=0.95, 95% CI=0.63, 1.27). The Q value was significant
(p,0.001), which implies that results across these studies were
heterogeneous. The fail-safe number of studies was 96.
The meta-regression was performed on account of heteroge-
neous effect sizes across studies. All the studies included in meta-
analysis were used Waldrop Scale or Modified Waldrop Scale.
Although the number of the scale items were varied, it did not
show significant to interpret the heterogeneous effect size with
unrestricted maximum likehood method (p=0.38). We also
examined sex ratio among patients, and sex ratio among
controls—but none of them were significant.
Patients with Schizophrenia vs. Unaffected Relatives
Six studies [7,13,22,23,24,27] reporting total MPA scores in
patients and relatives were included in the second meta-analysis
(Figure 3). Table 1 displays the mean effect sizes for these studies,
which included 339 patients and 303 relatives of individuals with
schizophrenia. The standard difference in means was 0.45 (95%
CI=0.29–0.62). The Q value was not significant (p=0.41),
indicating that these effect sizes were homogeneous. The fail-safe
number of studies was 16.
Unaffected Relatives vs. Healthy Controls
Six studies [7,13,22,23,24,27] reported total MPAs scores of
relatives and controls, which were included in the third meta-
analysis. Figure 4 shows the individual studies that were included
in this comparison. Table 1 displays the mean effect sizes for 303
relatives and 266 controls. The standard difference in means was
0.32, with a 95% CI=20.08, 0.73, which included 0. The fail-safe
number of studies was 8.
Individual MPA Items
Ten studies provided the frequency of specific MPA scale items
in patients and controls [8,9,12,26,27,30,32,33,34,35]. Table 2
summarizes the pooled results for individual items reported in $3
studies. The majority of MPA items were significant, indicating an
increased frequency of those items in patients with schizophrenia.
The results were homogeneous except for six items (high/steepled
palate, furrowed tongue, epicanthus, cleft palate, telecanthus, and
big gap between the first and second toes).
Discussion
In the present study we reviewed the updated literature on
MPAs in patients with schizophrenia, unaffected biological
relatives, and healthy controls. The combined effect size
comparing patients and controls was 0.95, which is consistent
with the Weinberg et al. study [5]. We also culled the studies of
unaffected relatives of patients with schizophrenia to investigate
whether MPAs may represent an endophenotype of schizophrenia.
The result of the comparison between patients with schizophrenia
and relatives of those with schizophrenia (d=0.45,) indicated a
moderate difference between them. On the other hand, the
difference between relatives of individuals with schizophrenia and
healthy controls (d=0.32) was non-significant. The forest plot
Table 2. Results of meta-analysis of individual MPA items in patients with schizophrenia and healthy controls.
Item N
No f
patients
No f
control Pooled ORs 95% CI p-value Q-value
Tongue with smooth-rough spots 5 272 322 9.86 (2.79, 34.91) 0.000 0.84
High/steepled palate 7 695 620 5.12 (3.00, 8.75) 0.000 28.26***
Single transverse palmar crease 9 808 815 4.77 (2.47, 9.21) 0.000 14.11
Furrowed tongue 9 811 744 4.28 (2.43, 7.55) 0.000 17.85*
Syndactyly of 2nd and 3rd toes 5 343 387 4.11 (1.31, 12.87) 0.015 4.54
Malformed ears 6 497 467 3.87 (1.80, 8.29) 0.001 1.89
Epicanthus 9 866 844 3.74 (2.16, 6.50) 0.000 25.51**
Low set ears 8 590 589 2.62 (1.25, 5.53) 0.011 4.16
Cleft palate 4 216 224 2.52 (1.13, 5.59) 0.024 11.46**
Telecanthus 7 497 467 2.34 (1.30, 4.21) 0.005 29.85***
Fine hair 3 183 208 2.30 (0.89, 5.97) 0.086 5.08
3rd toe longer than 2nd 3 136 165 2.25 (0.52, 9.68) 0.278 2.04
Head circumference 5 303 345 2.17 (1.12, 4.23) 0.022 1.74
Hair whorls 5 394 438 2.14 (0.97, 4.69) 0.059 5.33
Soft and pliable ears 3 183 208 2.07 (0.66, 6.53) 0.212 2.26
Curved fifth finger 7 439 438 2.04 (1.19, 3.50) 0.010 11.33
3rd toe equal to 2nd 4 243 270 2.01 (0.71, 5.69) 0.187 2.70
Asymmetrical ears 6 494 525 1.84 (0.80, 4.26) 0.152 1.88
Big gap between 1st and 2nd toes 6 343 387 1.43 (0.76, 2.68) 0.267 11.38*
Adherent ear lobes 9 808 815 1.26 (0.78, 2.03) 0.343 7.82
*p,0.05,
**p,0.01,
***p,0.001.
doi:10.1371/journal.pone.0024129.t002
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and controls were inconsistent. Therefore, further evidence for
MPAs as an endophenotype is necessary, particularly pertaining to
the criterion of the marker being present in unaffected family
members at a higher rate than in the general population.
Regarding our results on individual MPAs, several studies have
investigated whether some items or body region may be more
informative than others [4,5]. Some studies expanded rating scales
and assessed previously unmeasured MPAs items [30,32,36], such
as the use of quantified anthropometric assessments (e.g., facial
measurements) in addition to traditional qualitative ratings (e.g., 1
or 2 for presence of the anomaly, 0 for absence); however, the
Waldrop scale [6] is currently the most commonly used. Although
the number of studies reporting on specific MPAs was limited, a
number of individual items had relatively high ORs, and most
results were homogeneous. Because most studies did not report on
individual items, more research is needed to determine which
items are most sensitive for schizophrenia. Schizophrenia is
commonly conceptualized as a neurodevelopmental disorder
[5,33]; thus, further studies about individual MPA items would
be helpful in better understanding the neurodevelopmental
underpinnings of the disorder.
It should be reminded that MPAs are not specific to
schizophrenia and are observed in other neurodevelopmental
disorders such as autism, learning disabilities, and may be
associated with other serious neuropsychiatric disorders such as
bipolar disorders and unipolar depression [4,23,37]. However,
although MPAs are by no means specific to schizophrenia, they
appear to be more prevalent among patients with schizophrenia
compared to patients with other neuropsychiatric and/or
neurodevelpmental disorders.
There are several limitations of the present study, the major one
being the small number of studies and limited data reported on
unaffected relatives. It should also be noted that the fail-safe
number of studies for the comparison between relatives and
healthy controls seems quite low. More studies should be
conducted in the near future to cross-validate the current findings.
In addition, the moderator analysis did not find any significant
variable to explain the heterogeneous results. Even so, our meta-
analysis result on the difference between patients with schizophre-
nia and controls was large and reliable. Since there is evidence that
MPAs can be a marker for all psychoses, rather than just
schizophrenia, it would be interesting to include in the meta-
analysis studies that have evaluated also individuals with other
types of psychosis. This might also apply to studies that may have
evaluated relatives of patients with non-schizophrenia type of
psychoses. However, the current meta-analysis does not address
this issue owing to the very limited number of available studies.
Although the evidence from first-degree relatives was not as
robust, it showed a tendency for relatives to have more MPAs than
controls. The data suggest that MPAs are a biological marker, and
possibly an endophenotype, for schizophrenia.
Taken together, these findings indicate that medium effect size
of MPAs have been demonstrated in patients with schizophrenia
as compared to healthy controls, and to a lesser extent in
unaffected relatives. These findings are consistent with the idea
that MPAs may represent a putative endophenotype for
schizophrenia. However, more research including first-degree
family members is warranted.
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